ClinicalTrials.gov
public full text
Public Domain
Coxib-inhibition of Duodenal Polyp Growth in FAP
Preliminary data indicate a protective effect on the development of duodenal polyps by coxib treatment. The hypothesis of the present study is that normal therapy doses of rofecoxib for 1 year would stop or reverse the development of premalignant adenomatous lesions in the duodenal mucosa of FAP patients.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)#901601
- The CHAMP-study: The CHemopreventive Effect of Lithium in Familial AdenoMatous Polyposis#899696
- Global burden and trends of stomach cancer, Colon and rectum cancer, peptic ulcer disease, and gastritis and duodenitis from 1990 to 2021: a systematic analysis for the global burden of disease study 2021#642290
- Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas#898663
- Curcumin for the Chemoprevention of Colorectal Cancer#908672
Record · ID 981237
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive